NASDAQ Biotech CEO Sells Shares Worth Approximately $20 Million After Exercising Stock Options

On March 2, Michael H. Davidson, CEO of Nasdaq-listed biotech NewAmsterdam Pharma Co. N.V. (NASDAQ: NAMS), exercised stock options on common shares and immediately sold an equal number of shares, generating approximately $14.8 million (about KRW 20 billion) in cash.

By exercising the options, Davidson’s common-share holdings temporarily rose above 600,000 shares. He sold at $33.25 per share, reducing his direct stake to around 170,000 shares. After the sale, his remaining common stock is valued at roughly $5.8 million (about KRW 8 billion).

Davidson still holds several hundred thousand unexercised stock options, which vest over four years based on continued service.

On February 18, the company reported its full-year 2025 financial results and corporate update, noting that its dyslipidemia treatment candidate, obicetrapib, is under regulatory review by the European Medicines Agency (EMA) as well as UK and Swiss authorities.

NewAmsterdam Pharma is conducting three Phase 3 trials—PREVAIL, REMBRANDT, and RUBENS—and aims to launch a new study in early-stage Alzheimer’s patients in 2026. As of December 31, 2025, the company held approximately $728.9 million in cash, cash equivalents, and marketable securities.

The company is a late-stage biotech developing a once-daily fixed-dose combination of the CETP inhibitor obicetrapib and ezetimibe for cardiovascular and metabolic disease patients who respond inadequately to or cannot tolerate existing therapies.

Davidson oversees multiple ongoing Phase 3 programs in the U.S. and Europe. Together with its European partner, Menarini, NewAmsterdam Pharma is preparing for a European market launch upon regulatory approval.